Answers are grounded in this paper and cite their sources.
Review demonstrates the rising burden and therapeutic landscape of steatotic liver disease in patients with cardiometabolic disorders, highlighting integration of metabolic therapies.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is linked to insulin resistance and cardiometabolic disorders. This review synthesizes current information on the epidemiology, pathophysiology, and treatment of MASLD and its progressive form, metabolic dysfunction– associated steatohepatitis (MASH), underscoring how to integrate established metabolic care with emerging treatments to address the growing MASLD burden.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: